



Accelerating access to vaccines through the ACT Accelerator & COVAX

WHO Executive Board
18 January 2021

State of Vaccines: key numbers (data as of 18 January 2021)

- 1st vaccination programme started **42 days ago**¹ (23 days in EU)
- To date, **40 million doses of vaccine** have been administered
 - 95% have been administered in top 10 countries
 - At least 7 different vaccines (3 platforms) have been administered²
- Vaccination has **started in 50 countries**
 - Including 40 HICs; 8 UMICs; 1 LMIC; 1 LIC


1. Dec. 8, 2020 in the UK (Pfizer); Dec. 5, 2020 in Russia (Gamaleya)

2. Pfizer, Moderna, Gamaleya, Sinovac, Sinopharm, Serum Institute of India, Bharat Biotech

State of Vaccines: geographies & products (data at 18 January 2021)


Total COVID-19 vaccine doses/100 people

NOTE: single doses, not the total number of people vaccinated



Number of countries using specific vaccine(s)

NOTE: 39 countries are using 1 vaccine;
11 countries using 2 vaccines



¹ NOTE: AZ/UK is approved by an SRA but for batch by batch release




COVAX Facility is in a strong position to vaccinate, with the aim of initiating deliveries in February

COVAX Deals


- 2 billion doses
- 6 products
- 5 producers
- >1 B in options

COVAX secured volume, in M doses



COVAX Donations

- *Principles for sharing COVID-19 Vaccine Doses with COVAX*
- published 18 Dec 2020
- discussion ongoing with potential donors




https://www.gavi.org/sites/default/files/covid/covax/COVAX_Principles-COVID-19-Vaccine-Doses-COVAX.pdf



COVAX Participant Countries are ready to begin administering COVID-19 vaccines

Country Readiness

- 88 of 92 AMC countries submitted Vaccine Request Form
- 124 country readiness assessments (incl. 64 AMC countries)



Regulatory Pathways for rapid in-country import & emergency use authorizations


Indemnification & Liability

- *model indemnification language* established (8 January 2021)
- *no-fault compensation mechanism* developed (end-January 2021)





Crucial importance of expediting regulatory review of key COVAX portfolio products *(approximately 2 billion of the 3 billion doses COVAX aims to contract will be ready for delivery in 2021¹)*



¹ Data as of 7 January 2021



Crucial actions to support COVAX Facility rollout in February

1. WHO Regulatory Review:

- expedite full data & review for priority contracted products (i.e. SII/AZ; SK Bio/AZ)
- process full dossiers submitted to date on other products (i.e. Sinopharm, Sinovac)

| Product Name | Manufacturer | Regulatory Status | Priority Review | Full Dossier | Regulatory Review | Regulatory Review | Regulatory Review | Regulatory Review |
|----------------|--------------|-------------------|-----------------|--------------|-------------------|-------------------|-------------------|-------------------|
| 2. AstraZeneca | AstraZeneca | Priority Review | Yes | Yes | Yes | Yes | Yes | Yes |
| 3. Sinopharm | Sinopharm | Priority Review | Yes | Yes | Yes | Yes | Yes | Yes |
| 4. Sinovac | Sinovac | Priority Review | Yes | Yes | Yes | Yes | Yes | Yes |
| 5. SII/AZ | SII/AZ | Priority Review | Yes | Yes | Yes | Yes | Yes | Yes |
| 6. SK Bio/AZ | SK Bio/AZ | Priority Review | Yes | Yes | Yes | Yes | Yes | Yes |

https://extranet.who.int/pgweb/sites/default/files/documents/Status_COVID_VAX_14Jan2021.pdf

2. COVAX Portfolio:

- immediately expand to include approved mRNA vaccine(s)
- rapidly explore potential early supply from other advanced candidates

3. Dose-Sharing: initiate donations to COVAX from key countries with bilateral-deals

4. In-Country Readiness: ensure regulatory authorizations and legal frameworks for indemnification & no-fault compensation are in place

COVAX & ACT-A in 2021: 3 big shifts will drive our priorities to accelerate development & equitable access to new COVID-19 tools

From:

Primarily **supply side problem** assuming **strong demand** for all tools

Stable virus with **uniform epi** & **response globally**

Strong global **multilateral commitment** of all key actors



To:

Universal & **unmet demand for vaccines** with suboptimal demand for diagnostics/Tx

Evolving viral mutations and variable epidemiology, urgency & response

Escalating bilateral deals and **suboptimal investment** in global solutions

A 'refreshed & prioritized' ACT-A Strategy & Needs for 2021 will be presented to the ACT-A Facilitation Council on 9 February 2021



Accelerating COVID-19 vaccine rollout globally

- COVAX aims to start deliveries in February
- **Countries with bilateral deals** are urged to be transparent with COVAX, prioritize COVAX's 'place in the queue' & dose share
- **Producers** are urged to rapidly provide full regulatory data to WHO, prioritize COVAX supply contracts & facilitate donations/dose-sharing
- **Countries introducing vaccines** are urged to only use products that meet rigorous international standards for safety, efficacy & quality (e.g. WHO EUL)
- **Donors** are urged to fully finance COVAX procurement & delivery and R&D to optimize products and address variants